Dale G. Schaar

RH Provider

Schaar_Dale_2017%29_Spring_SH.jpg

Dale G. Schaar, MD, PhD

Specialties:
Hematologic malignancies, bone marrow transplants, leukemia, lymphoma, blood cancers

Academic Appointments:
  • Director of Myeloid Malignancies
  • Professor of Medicine
  • Rutgers Robert Wood Johnson Medical School
Aetna US HealthCare
Aetna, Inc.
AmeriGroup
AmeriHealth HMO
Champ VA
CIGNA
Cigna Healthcare
Emblem Health
GHI
Health Republic
HealthFirst
Horizon
QualCare
Horizon NJ Health, Inc.
Magnacare
Medicaid
Medicare
Multiplan
Oxford Health Plans
Private Healthcare Systems
Qualcare HMO
Qualcare PPO
Tricare
United Healthcare
United Healthcare Community Plan
Provider Biography

I have been a member of the Rutgers Cancer Institute of New Jersey since 2002 having completed a fellowship in medical oncology at Rutgers University, which was preceded by my residency in Internal Medicine at the University of Maryland.

I specialize in the care of patients with blood cell cancers with a focus on the myeloid disorders including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).  In addition, I am one of the blood and bone marrow transplant physicians here at Rutgers Cancer Institute and therefore, am able to manage all levels of treatment that may be required for these complex blood disorders. I am able to provide patients with a comprehensive evaluation, and through consultation with the multidisciplinary teams within the Leukemia/Lymphoma/Hematologic Malignancies and Stem Cell Transplant Programs, I help educate patients on their treatment options so they can make informed decisions regarding their care.

In addition to my 25 years of basic scientific research experience, I have clinical research interest in developing new treatment strategies for MDS and have established Rutgers Cancer Institute as one of the Centers of Excellence for MDS treatment as recognized by the MDS Foundation. I also direct clinical trials for patients with acute leukemia (AML and acute lymphoblastic leukemia), including studies for patients who have not responded adequately to first line therapies.  Here at Rutgers Cancer Institute, through resources that are only available at a National Cancer Institute-designated Comprehensive Cancer Center, we are well equipped to manage complex blood cells cancers and provide cutting edge therapies for these disorders.